A Phase 3 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 39 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 24th largest by enrollment, is one of 3 that started in 2006, is one of 26 in phase 3, and was the 16th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 21st largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2006, is one of 22 in phase 3, and was the 18th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the safety of chronic use of abatacept in Japanese Subjects with Rheumatoid Arthritis (RA) having completed clinical studies IM101-071, IM101-034, and also Disease Modifying Anti-Rheumatic Drugs (DMARDs) failures with MTX intolerance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept
Drug: Abatacept
Drug: Abatacept
Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
Also known as: Orencia®, BMS-188667
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs
AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. Both subjective and objective AEs and SAEs are included.
Time frame: From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Number of Participants With Abnormal Laboratory Changes (ALC)
The laboratory tests were analyses included enzyme, gastrointestinal, hematology, hepatobiliary, lipid, metabolic, nutritional, blood gas, microbiology, serology, protein, chemistry, renal, urinary tract, urinalyses, water, electrolyte and mineral investigations.
Time frame: From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Number of Participants With Vital Signs, Physical Examinations, and Electrocardiogram Findings That Were Considered to be AEs by the Investigator
Time frame: At week 0, 2, 4; then once every 4 weeks up to 48 months; then once in every 3 months or 12 weeks to end of study (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Percentage of Participants With American College of Rheumatology (ACR 20) Response Over Time
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
Time frame: At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.
Percentage of Participants With ACR 50 Response Over Time
ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
Time frame: At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.
Percentage of Participants With ACR 70 Response Over Time
ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
Time frame: At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.
Baseline (BL) and Postbaseline (PBL) Disease Activity Scores (DAS 28)
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (change of \> 5.1), low disease activity (change of ≤ 3.2) and remission (\< 2.6). Please see outcome 8 for change from BL data.
Time frame: At BL (week 0), week 24, 48, 96, 144, and 192.
Change From Baseline in DAS 28 Scores at Week 24, 48, 96, 144, and 192
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Please refer to outcome 7 for BL and PBL values.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Number of Participants With DAS 28 Score Change ≥ 1.2 From Baseline at Weeks 24, 48, 96, 144, and 192
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score change ≥ 1.2 from BL were considered to have improvement.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Number of Participants With Low Disease Activity Score (DAS 28 Score ≤ 3.2) at Weeks 24, 48, 96, 144, 192
The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score ≤ 3.2 were considered to have low disease activity.
Time frame: At weeks 24, 48, 96, 144, and 192.
Number of Participants in Remission (DAS 28 Score < 2.6) at Weeks 24, 48, 96, 144, 192
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score \< 2.6 were considered to be in remission.
Time frame: At weeks 24, 48, 96, 144, and 192.
Percentage of Participants Who Achieved a Reduction of At Least 0.3 Units From Baseline in Health Assessment Questionnaire (HAQ) at Weeks 24, 48, 96, 144, 192
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from BL in HAQ.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Baseline and Postbaseline Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Scores
The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 14 for change from BL data.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Change From Baseline in Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192
The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \>3 points were considered clinically meaningful. Please see outcome 13 for BL and PBL values.
Time frame: At baseline (week 0), weeks 24, 48, 96, 144, and 192.
Baseline and Postbaseline Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Scores
The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful. Please see outcome 14 for change from BL data.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Change From Baseline in Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192
The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 15 for BL and PBL values.
Time frame: At BL (Week 0), weeks 24, 48, 96, 144, and 192.
Baseline and Postbaseline C-reactive Protein (CRP) Levels
CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease. Please see outcome 18 for change from BL data.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Percentage Decrease in C-reactive Protein Levels From Baseline at Weeks 24, 48, 96, 144, and 192
CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease, negative values indicate improvement. Percentage improvement from BL = (BL - PBL value) / BL value \* 100. Please refer to outcome 17 for BL and PBL values.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Baseline and Postbaseline Rheumatoid Factor Levels
Rheumatoid factor (RF or RhF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please see outcome 20 for change from BL data.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Change From Baseline in Rheumatoid Factor Levels at Weeks 24, 48, 96, 144, and 192
RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please refer to outcome 19 for BL and PBL values.
Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.
Number of Participants Who Were Positive for Anti-abatacept and Anti-CTLA4-T Antibodies
Validated enzyme-linked immunoassay (ELISA) method was used to measure anti-abatacept and anti-CTLA4-T antibody levels. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed.
Time frame: At BL (week 0), weeks 24, 48, 72, 96, 120, 144, 168, and 192.
Abatacept PK Parameter: Total Body Clearance
Total body clearance is the rate and extent at which the drug is eliminated from the body. The clearance of a drug is used to understand the processes involved in drug elimination, distribution and metabolism.
Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Abatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State
Area under the plasma concentration-time curve (AUCss) at steady state for each dosing interval was determined using the linear trapezoidal rule.
Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Abatacept PK Parameter: Maximum Serum Concentration at Steady State
Maximum plasma concentration is the maximum observed serum drug concentration at steady state (Css max).
Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Abatacept PK Parameter: Minimum Plasma Concentration at Steady State
Minimum Plasma Concentration (Cmin) is the minimum observed serum drug concentration at steady state.
Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
| Milestone | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Started | 13 | 178 | 26 |
| Completed | 10 | 142 | 10 |
| Not completed | 3 | 36 | 16 |
| Withdrew: Adverse event | 1 | 17 | 5 |
| Withdrew: Withdrawal by subject | 0 | 7 | 6 |
| Withdrew: Inadequate response | 2 | 7 | 4 |
| Withdrew: Other reason | 0 | 5 | 1 |
| Milestone | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Started | 10 | 142 | 10 |
| Completed | 10 | 141 | 10 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. Both subjective and objective AEs and SAEs are included.
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| SAEs | 4 | 50 | 14 |
| Drug-related SAEs | 2 | 26 | 9 |
| AEs | 13 | 176 | 24 |
| Drug-related AEs | 13 | 165 | 24 |
| Discontinuation due to SAEs | 0 | 14 | 5 |
| Discontinuation due to AEs | 1 | 18 | 5 |
| Deaths | 0 | 1 | 0 |
ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
| percentage of participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 4; (n=13, 178,26) | 30.8 (9.1 to 61.4) | 29.2 (22.7 to 36.5) | 34.6 (17.2 to 55.7) |
| Week 12; (n=13, 178,24) | 76.9 (46.2 to 95.0) | 47.2 (39.7 to 54.8) | 58.3 (36.6 to 77.9) |
| Week 24; (n=13, 176, 23) | 76.9 (46.2 to 95.0) | 59.7 (52.0 to 67.0) | 78.3 (56.3 to 92.5) |
| Week 36; (n=13, 175, 20) | 69.2 (38.6 to 90.9) | 61.7 (54.1 to 68.9) | 90.0 (68.3 to 98.8) |
| Week 48; (n=13, 170, 18) | 61.5 (31.6 to 86.1) | 63.5 (55.8 to 70.8) | 88.9 (65.3 to 98.6) |
| Week 60; (n=13, 165, 17) | 69.2 (38.6 to 90.9) | 69.7 (62.1 to 76.6) | 94.1 (71.3 to 99.9) |
| Week 72; (n=13, 161, 17) | 84.6 (54.6 to 98.1) | 67.7 (59.9 to 74.8) | 94.1 (71.3 to 99.9) |
| Week 84; (n=13, 161, 17) | 61.5 (31.6 to 86.1) | 67.1 (59.2 to 74.3) | 100.0 (80.5 to 100.0) |
| Week 96; (n=13, 160, 17) | 69.2 (38.6 to 90.9) | 63.8 (55.8 to 71.2) | 82.4 (56.6 to 96.2) |
| Week 108; (n=13, 156, 15) | 53.8 (25.1 to 80.8) | 67.9 (60.0 to 75.2) | 100.0 (78.2 to 100.0) |
| Week 120; (n=13, 154, 15) | 69.2 (38.6 to 90.9) | 69.5 (61.6 to 76.6) | 100.0 (78.2 to 100.0) |
| Week 132; (n=13, 151, 14) | 61.5 (31.6 to 86.1) | 68.9 (60.8 to 76.2) | 100.0 (76.8 to 100.0) |
| Week 144; (n=12, 142, 13) | 58.3 (27.7 to 84.8) | 69.7 (61.5 to 77.1) | 84.6 (54.6 to 98.1) |
| Week 156; (n=11, 113, 12) | 63.6 (30.8 to 89.1) | 66.4 (56.9 to 75.0) | 100.0 (73.5 to 100.0) |
| Week 168; (n=10, 80, 8) | 80.0 (44.4 to 97.5) | 71.3 (60.0 to 80.8) | 100.0 (63.1 to 100.0) |
| Week 180; (n=8, 56, 4) | 62.5 (24.5 to 91.5) | 69.6 (55.9 to 81.2) | 100.0 (39.8 to 100.0) |
| Week 192; (n=3, 7, 1) | 66.7 (9.4 to 99.2) | 85.7 (42.1 to 99.6) | 100.0 (2.5 to 100.0) |
ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
| percentage of participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 4; (n=13, 178, 26) | 15.4 (1.9 to 45.4) | 6.2 (3.1 to 10.8) | 0 (0 to 13.2) |
| Week 12; (n=13, 178,24) | 38.5 (13.9 to 68.4) | 16.3 (11.2 to 22.6) | 29.2 (12.6 to 51.1) |
| Week 24; (n=13, 176, 23) | 30.8 (9.1 to 61.4) | 25.6 (19.3 to 32.7) | 47.8 (26.8 to 69.4) |
| Week 36; (n=13, 175, 20) | 38.5 (13.9 to 68.4) | 28.6 (22.0 to 35.9) | 50.0 (27.2 to 72.8) |
| Week 48; (n=13, 170, 18) | 15.4 (1.9 to 45.4) | 38.8 (31.5 to 46.6) | 72.2 (46.5 to 90.3) |
| Week 60; (n=13, 165, 17) | 30.8 (9.1 to 61.4) | 42.4 (34.8 to 50.3) | 58.8 (32.9 to 81.6) |
| Week 72; (n=13, 161, 17) | 46.2 (19.2 to 74.9) | 43.5 (35.7 to 51.5) | 70.6 (44.0 to 89.7) |
| Week 84; (n=13, 161, 17) | 38.5 (13.9 to 68.4) | 42.2 (34.5 to 50.3) | 70.6 (44.0 to 89.7) |
| Week 96; (n=13, 160, 17) | 23.1 (5.0 to 53.8) | 38.1 (30.6 to 46.1) | 58.8 (32.9 to 81.6) |
| Week 108; (n=13, 156, 15) | 23.1 (5.0 to 53.8) | 42.3 (34.4 to 50.5) | 66.7 (38.4 to 88.2) |
| Week 120; (n=13, 154, 15) | 46.2 (19.2 to 74.9) | 45.5 (37.4 to 53.7) | 93.3 (68.1 to 99.8) |
| Week 132; (n=13, 151, 14) | 38.5 (13.9 to 68.4) | 43.7 (35.7 to 52.0) | 85.7 (57.2 to 98.2) |
| Week 144; (n=12, 142, 13) | 25.0 (5.5 to 57.2) | 47.2 (38.8 to 55.7) | 69.2 (38.6 to 90.9) |
| Week 156; (n=11, 113, 12) | 36.4 (10.9 to 69.2) | 47.8 (38.3 to 57.4) | 83.3 (51.6 to 97.9) |
| Week 168; (n=10, 80, 8) | 30.0 (6.7 to 65.2) | 47.5 (36.2 to 59.0) | 87.5 (47.3 to 99.7) |
| Week 180; (n=8, 56, 4) | 12.5 (0.3 to 52.7) | 51.8 (38.0 to 65.3) | 75.0 (19.4 to 99.4) |
| Week 192; (n=3, 7, 1) | 66.7 (9.4 to 99.2) | 71.4 (29.0 to 96.3) | 100.0 (2.5 to 100.0) |
ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.
| percentage of participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 4; (n=13, 178, 26) | 7.7 (0.2 to 36.0) | 0 (0 to 2.1) | 0 (0 to 13.2) |
| Week 12; (n=13, 178, 24) | 7.7 (0.2 to 36.0) | 5.6 (2.7 to 10.1) | 8.3 (1.0 to 27.0) |
| Week 24; (n=13, 176, 23) | 7.7 (0.2 to 36.0) | 10.8 (6.6 to 16.3) | 21.7 (7.5 to 43.7) |
| Week 36; (n=13, 175, 20) | 15.4 (1.9 to 45.4) | 11.4 (7.1 to 17.1) | 20.0 (5.7 to 43.7) |
| Week 48; (n=13, 170, 18) | 15.4 (1.9 to 45.4) | 15.3 (10.2 to 21.6) | 27.8 (9.7 to 53.5) |
| Week 60; (n=13, 165, 17) | 15.4 (1.9 to 45.4) | 19.4 (13.7 to 26.3) | 29.4 (10.3 to 56.0) |
| Week 72; (n=13, 161, 17) | 15.4 (1.9 to 45.4) | 18.6 (12.9 to 25.5) | 23.5 (6.8 to 49.9) |
| Week 84; (n=13, 161, 17) | 7.7 (0.2 to 36.0) | 17.4 (11.9 to 24.1) | 23.5 (6.8 to 49.9) |
| Week 96; (n=13, 160, 17) | 7.7 (0.2 to 36.0) | 19.4 (13.6 to 26.4) | 23.5 (6.8 to 49.9) |
| Week 108; (n=13, 156, 15) | 7.7 (0.2 to 36.0) | 15.4 (10.1 to 22.0) | 33.3 (11.8 to 61.6) |
| Week 120; (n=13, 154, 15) | 7.7 (0.2 to 36.0) | 19.5 (13.5 to 26.6) | 46.7 (21.3 to 73.4) |
| Week 132; (n=13, 151, 14) | 0 (0 to 24.7) | 20.5 (14.4 to 27.9) | 42.9 (17.7 to 71.1) |
| Week 144; (n=12, 142, 13) | 0 (0 to 26.5) | 21.8 (15.3 to 29.5) | 23.1 (5.0 to 53.8) |
| Week 156; (n=11, 113, 12) | 0 (0 to 28.5) | 25.7 (17.9 to 34.7) | 33.3 (9.9 to 65.1) |
| Week 168; (n=10, 80, 8) | 0 (0 to 30.8) | 27.5 (18.1 to 38.6) | 62.5 (24.5 to 91.5) |
| Week 180; (n=8, 56, 4) | 0 (0 to 36.9) | 33.9 (21.8 to 47.8) | 50.0 (6.8 to 93.2) |
| Week 192; (n=3, 7, 1) | 0 (0 to 70.8) | 14.3 (0.4 to 57.9) | 100.0 (2.5 to 100.0) |
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (change of \> 5.1), low disease activity (change of ≤ 3.2) and remission (\< 2.6). Please see outcome 8 for change from BL data.
| Units on a Scale | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24- BL (n=13, 176, 21) | 4.4 ± 1.0 | 4.8 ± 1.4 | 6.3 ± 1.0 |
| Week 24- PBL (n=13, 176, 21) | 3.0 ± 1.1 | 3.2 ± 1.1 | 4.0 ± 1.9 |
| Week 48- BL (n=13, 168, 18) | 4.4 ± 1.0 | 4.8 ± 1.4 | 6.3 ± 1.0 |
| Week 48- PBL (n=13, 168, 18) | 3.0 ± 1.1 | 2.9 ± 1.1 | 3.5 ± 1.4 |
| Week 96- BL (n=13, 159, 17) | 4.4 ± 1.0 | 4.8 ± 1.4 | 6.2 ± 1.0 |
| Week 96- PBL (n=13, 159, 17) | 3.3 ± 1.0 | 2.8 ± 1.0 | 3.2 ± 1.0 |
| Week 144- BL (n=12, 142, 13) | 4.3 ± 0.9 | 4.9 ± 1.4 | 6.3 ± 1.0 |
| Week 144- PBL (n=12, 142, 13) | 3.0 ± 0.9 | 2.8 ± 1.0 | 3.2 ± 1.2 |
| Week 192- BL (n=3, 7, 1) | 4.6 ± 1.6 | 5.4 ± 0.9 | 7.9 ± NA |
| Week 192- PBL (n=3, 7, 1) | 2.6 ± 1.2 | 3.1 ± 1.4 | 1.9 ± NA |
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Please refer to outcome 7 for BL and PBL values.
| Units on a Scale | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 21) | -1.4 (-2.0 to -0.8) | -1.7 (-1.8 to -1.5) | -2.3 (-2.9 to -1.7) |
| Week 48 (n=13, 168, 18) | -1.4 (-2.0 to -0.9) | -1.9 (-2.1 to -1.7) | -2.8 (-3.3 to -2.3) |
| Week 96 (n=13, 159, 17) | -1.1 (-1.7 to -0.6) | -2.0 (-2.3 to -1.8) | -3.0 (-3.6 to -2.4) |
| Week 144 (n=12, 142, 13) | -1.3 (-1.8 to -0.8) | -2.1 (-2.3 to -1.9) | -3.1 (-4.0 to -2.2) |
| Week 192 (n=3, 7, 1) | -2.0 (-3.4 to -0.6) | -2.3 (-3.6 to -1.1) | -6.0 (NA to NA) |
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score change ≥ 1.2 from BL were considered to have improvement.
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 21) | 9 | 113 | 17 |
| Week 48 (n=13, 168, 18) | 8 | 114 | 16 |
| Week 96 (n=13, 159, 17) | 7 | 111 | 16 |
| Week 144 (n=12, 142, 13) | 6 | 107 | 12 |
| Week 192 (n=3, 7, 1) | 3 | 5 | 1 |
The laboratory tests were analyses included enzyme, gastrointestinal, hematology, hepatobiliary, lipid, metabolic, nutritional, blood gas, microbiology, serology, protein, chemistry, renal, urinary tract, urinalyses, water, electrolyte and mineral investigations.
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Participants with Serious ALC | 0 | 0 | 1 |
| Discontinuations due Serious ALC | 0 | 0 | 0 |
| Participants with drug related Serious ALC | 0 | 0 | 1 |
| Participants with ALC | 0 | 1 | 0 |
| Discontinuations due ALC | 7 | 125 | 19 |
| Discontinuations due ALC | 6 | 102 | 13 |
The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score ≤ 3.2 were considered to have low disease activity.
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 21) | 9 | 95 | 6 |
| Week 48 (n=13, 168, 18) | 9 | 105 | 7 |
| Week 96 (n=13, 159, 17) | 6 | 101 | 6 |
| Week 144 (n=12, 142, 13) | 6 | 95 | 7 |
| Week 192 (n=3, 7, 1) | 2 | 3 | 1 |
The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score \< 2.6 were considered to be in remission.
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 21) | 6 | 60 | 6 |
| Week 48 (n=13, 168, 18) | 4 | 75 | 5 |
| Week 96 (n=13, 159, 17) | 3 | 75 | 5 |
| Week 144 (n=12, 142, 13) | 4 | 71 | 3 |
| Week 192 (n=3, 7, 1) | 2 | 2 | 1 |
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from BL in HAQ.
| percentage of participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 23) | 38.5 (13.9 to 68.4) | 39.2 (31.9 to 46.8) | 52.2 (30.6 to 73.2) |
| Week 48 (n=13, 170, 18) | 30.8 (9.1 to 61.4) | 41.2 (33.7 to 49.0) | 77.8 (52.4 to 93.6) |
| Week 96 (n=13, 160, 17) | 46.2 (19.2 to 74.9) | 47.5 (39.6 to 55.5) | 76.5 (50.1 to 93.2) |
| Week 144 (n=12, 142, 13) | 50.0 (21.1 to 78.9) | 48.6 (40.1 to 57.1) | 69.2 (38.6 to 90.9) |
| Week 192 (n=3, 7, 1) | 100.0 (29.2 to 100.0) | 85.7 (42.1 to 99.6) | 100.0 (2.5 to 100.0) |
The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 14 for change from BL data.
| Units on a Scale | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24- BL (n=13, 176, 23) | 34.2 ± 14.5 | 30.3 ± 15.2 | 19.0 ± 12.5 |
| Week 24- PBL (n=13, 176, 23) | 40.6 ± 12.6 | 38.5 ± 14.3 | 30.3 ± 17.1 |
| Week 48- BL (n=13, 170, 18) | 34.2 ± 14.5 | 30.4 ± 15.2 | 20.1 ± 12.4 |
| Week 48- PBL (n=13, 170, 18) | 40.9 ± 11.1 | 40.1 ± 13.7 | 37.1 ± 14.0 |
| Week 96- BL (n=13, 160, 17) | 34.2 ± 14.5 | 29.8 ± 15.2 | 19.9 ± 12.7 |
| Week 96- PBL (n=13, 160, 17) | 38.7 ± 12.6 | 40.3 ± 13.2 | 37.5 ± 13.5 |
| Week 144- BL (n=12, 142, 13) | 32.9 ± 14.4 | 30.6 ± 15.1 | 21.1 ± 14.0 |
| Week 144- PBL (n=12, 142, 13) | 37.8 ± 14.5 | 39.2 ± 13.7 | 32.9 ± 14.2 |
| Week 192- BL (n=3, 7, 1) | 24.6 ± 10.9 | 22.8 ± 12.2 | 12.5 ± NA |
| Week 192- PBL (n=3, 7, 1) | 30.4 ± 24.8 | 38.5 ± 16.1 | 37.0 ± NA |
The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \>3 points were considered clinically meaningful. Please see outcome 13 for BL and PBL values.
| Units on a Scale | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 23) | 6.5 (0 to 13.0) | 8.2 (6.4 to 10.0) | 11.3 (5.2 to 17.5) |
| Week 48 (n=13, 170, 18) | 6.7 (0.3 to 13.1) | 9.7 (7.7 to 11.7) | 17.1 (11.1 to 23.0) |
| Week 96 (n=13, 160, 17) | 4.5 (-4.5 to 13.6) | 10.4 (8.5 to 12.4) | 17.6 (9.7 to 25.5) |
| Week 144 (n=12, 142, 13) | 4.8 (-5.3 to 14.9) | 8.6 (6.6 to 10.6) | 11.8 (4.4 to 19.1) |
| Week 192 (n=3, 7, 1) | 5.7 (-79.9 to 91.4) | 15.7 (0.7 to 30.8) | 24.6 (NA to NA) |
The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful. Please see outcome 14 for change from BL data.
| Units on a Scale | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24- BL (n=13, 176, 23) | 41.6 ± 12.4 | 48.6 ± 8.5 | 41.7 ± 9.8 |
| Week 24- PBL (n=13, 176, 23) | 45.2 ± 8.9 | 51.2 ± 7.5 | 49.5 ± 10.5 |
| Week 48- BL (n=13, 170, 18) | 41.6 ± 12.4 | 48.6 ± 8.5 | 43.2 ± 9.6 |
| Week 48- PBL (n=13, 170, 18) | 49.0 ± 8.0 | 51.6 ± 8.1 | 49.9 ± 7.5 |
| Week 96- BL (n=13, 160, 17) | 41.6 ± 12.4 | 48.6 ± 8.5 | 43.6 ± 9.8 |
| Week 96- PBL (n=13, 160, 17) | 49.9 ± 7.2 | 50.6 ± 7.5 | 51.6 ± 8.2 |
| Week 144- BL (n=12, 142, 13) | 41.6 ± 13.0 | 48.5 ± 8.6 | 42.2 ± 9.4 |
| Week 144- PBL (n=12, 142, 13) | 51.1 ± 7.6 | 50.6 ± 7.3 | 51.1 ± 8.4 |
| Week 192- BL (n=3, 7, 1) | 45.7 ± 20.4 | 45.4 ± 8.1 | 37.1 ± NA |
| Week 192- PBL (n=3, 7, 1) | 60.7 ± 6.1 | 52.4 ± 12.5 | 69.3 ± NA |
The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 15 for BL and PBL values.
| Units on a Scale | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 23) | 3.6 (-1.3 to 8.6) | 2.6 (1.5 to 3.7) | 7.7 (1.7 to 13.8) |
| Week 48 (n=13, 170, 18) | 7.4 (2.5 to 12.3) | 3.0 (1.7 to 4.3) | 6.7 (1.4 to 11.9) |
| Week 96 (n=13, 160, 17) | 8.3 (2.0 to 14.6) | 2.1 (0.7 to 3.4) | 8.0 (1.9 to 14.2) |
| Week 144 (n=12, 142, 13) | 9.5 (3.4 to 15.6) | 2.1 (0.8 to 3.5) | 8.9 (1.9 to 15.9) |
| Week 192 (n=3, 7, 1) | 15.0 (-49.5 to 79.6) | 7.0 (-5.2 to 19.3) | 32.1 (NA to NA) |
CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease. Please see outcome 18 for change from BL data.
| mg/dL | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24- BL (n=13, 176, 21) | 1.8 ± 2.8 | 2.3 ± 2.2 | 3.9 ± 3.1 |
| Week 24- PBL (n=13, 176, 21) | 0.7 ± 0.7 | 0.8 ± 1.3 | 1.9 ± 2.5 |
| Week 48- BL (n=13, 168, 18) | 1.8 ± 2.8 | 2.2 ± 2.1 | 4.1 ± 3.1 |
| Week 48- PBL (n=13, 168, 18) | 1.1 ± 2.1 | 0.6 ± 1.1 | 0.9 ± 1.3 |
| Week 96- BL (n=13, 159, 17) | 1.8 ± 2.8 | 2.3 ± 2.2 | 4.1 ± 3.2 |
| Week 96- PBL (n=13, 159, 17) | 0.9 ± 1.3 | 0.5 ± 0.9 | 1.0 ± 1.0 |
| Week 144- BL (n=12, 142, 13) | 1.9 ± 2.9 | 2.4 ± 2.2 | 4.2 ± 3.4 |
| Week 144- PBL (n=12, 142, 13) | 1.2 ± 1.4 | 0.6 ± 1.5 | 0.6 ± 0.6 |
| Week 192- BL (n=3, 7, 1) | 4.6 ± 5.4 | 1.7 ± 1.2 | 8.4 ± NA |
| Week 192- PBL (n=3, 7, 1) | 1.4 ± 1.7 | 0.8 ± 1.6 | 0.2 ± NA |
CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease, negative values indicate improvement. Percentage improvement from BL = (BL - PBL value) / BL value \* 100. Please refer to outcome 17 for BL and PBL values.
| percentage improvement | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 21) | -18.4 (-147.8 to 111.1) | 30.5 (-0.4 to 61.4) | 60.2 (42.7 to 77.7) |
| Week 48 (n=13, 168, 18) | 12.0 (-35.9 to 59.9) | 31.9 (8.7 to 55.1) | 77.8 (65.2 to 90.3) |
| Week 96 (n=13, 159, 17) | -3.3 (-77.9 to 71.3) | 40.5 (21.8 to 59.1) | 70.1 (51.0 to 89.2) |
| Week 144 (n=12, 142, 13) | -71.9 (-188.7 to 44.9) | -39.3 (-191.5 to 113.0) | 79.9 (68.0 to 91.7) |
| Week 192 (n=3, 7, 1) | 67.9 (52.0 to 83.7) | 39.7 (-83.2 to 162.6) | 97.4 (NA to NA) |
Rheumatoid factor (RF or RhF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please see outcome 20 for change from BL data.
| IU/mL | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24- BL (n=13, 176, 21) | 200.2 ± 343.8 | 214.3 ± 383.3 | 630.8 ± 873.4 |
| Week 24- PBL (n=13, 176, 21) | 127.5 ± 191.6 | 141.0 ± 289.2 | 573.9 ± 897.2 |
| Week 48- BL (n=13, 168, 18) | 200.2 ± 343.8 | 217.3 ± 389.7 | 560.9 ± 893.0 |
| Week 48- PBL (n=13, 168, 18) | 139.9 ± 241.8 | 149.5 ± 288.4 | 288.3 ± 482.8 |
| Week 96- BL (n=13, 159, 17) | 200.2 ± 343.8 | 215.9 ± 393.9 | 590.9 ± 911.1 |
| Week 96- PBL (n=13, 159, 17) | 186.9 ± 339.4 | 151.0 ± 285.8 | 216.8 ± 329.2 |
| Week 144- BL (n=12, 142, 13) | 205.6 ± 358.5 | 229.0 ± 412.6 | 639.4 ± 990.8 |
| Week 144- PBL (n=12, 142, 13) | 211.3 ± 359.8 | 173.7 ± 360.8 | 361.6 ± 663.9 |
| Week 192- BL (n=3, 7, 1) | 314.3 ± 455.3 | 253.7 ± 307.6 | 2800.0 ± NA |
| Week 192- PBL (n=3, 7, 1) | 315.0 ± 307.0 | 348.4 ± 521.6 | 197.0 ± NA |
RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please refer to outcome 19 for BL and PBL values.
| IU/mL | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Week 24 (n=13, 176, 21) | -72.6 (-197.5 to 52.2) | -73.2 (-102.8 to -43.7) | -56.9 (-149.5 to 35.7) |
| Week 48 (n=13, 168, 18) | -60.2 (-137.9 to 17.4) | -67.8 (-100.4 to -35.2) | -272.6 (-494.0 to -51.2) |
| Week 96 (n=13, 159, 17) | -13.2 (-63.3 to 36.8) | -64.9 (-103.3 to -26.6) | -374.1 (-704.9 to -43.2) |
| Week 144 (n=12, 142, 13) | 5.7 (-43.0 to 54.4) | -55.3 (-97.2 to -13.3) | -277.8 (-708.2 to 152.7) |
| Week 192 (n=3, 7, 1) | 0.7 (-471.3 to 472.7) | 94.7 (-122.5 to 311.9) | -2603 (NA to NA) |
Validated enzyme-linked immunoassay (ELISA) method was used to measure anti-abatacept and anti-CTLA4-T antibody levels. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed.
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Positive for anti-abatacept antibody | 2 | 19 | 2 |
| Positive for anti-CTLA4-T antibody | 0 | 19 | 1 |
Total body clearance is the rate and extent at which the drug is eliminated from the body. The clearance of a drug is used to understand the processes involved in drug elimination, distribution and metabolism.
| L/day | All Participants From IM101-129 Study |
|---|---|
| Abatacept PK Parameter: Total Body Clearance | 0.306 ± 0.098 |
Area under the plasma concentration-time curve (AUCss) at steady state for each dosing interval was determined using the linear trapezoidal rule.
| µg*h/mL | All Participants From IM101-129 Study |
|---|---|
| Abatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State | 42959.94 ± 12763.45 |
Maximum plasma concentration is the maximum observed serum drug concentration at steady state (Css max).
| µg/mL | All Participants From IM101-129 Study |
|---|---|
| Abatacept PK Parameter: Maximum Serum Concentration at Steady State | 241.62 ± 73.96 |
Minimum Plasma Concentration (Cmin) is the minimum observed serum drug concentration at steady state.
| µg/mL | All Participants From IM101-129 Study |
|---|---|
| Abatacept PK Parameter: Minimum Plasma Concentration at Steady State | 26.14 ± 23.10 |
| participants | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| Blood pressure increased | 2 | 27 | 12 |
| Blood pressure decreased | 1 | 11 | 1 |
| Blood pressure diastolic decreased | 0 | 7 | 0 |
| Blood pressure systolic increased | 0 | 3 | 2 |
| Weight decreased | 0 | 5 | 0 |
| Weight increased | 0 | 3 | 1 |
| Body temperature decreased | 0 | 3 | 0 |
| Body temperature increased | 0 | 2 | 0 |
| Blood pressure systolic decreased | 1 | 1 | 1 |
| Blood pressure diastolic increased | 0 | 1 | 0 |
| Electrocardiogram abnormal | 0 | 1 | 0 |
| Electrocardiogram ST segment depression | 0 | 1 | 0 |
| Electrocardiogram ST-T segment abnormal | 0 | 1 | 0 |
| Heart rate increased | 0 | 2 | 0 |
| Heart rate decreased | 0 | 1 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | — | 4/13 (30.8%) | 13/13 (100%) |
| Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | — | 50/178 (28.1%) | 176/178 (98.9%) |
| New Participants With MTX Intolerance; Abatacept 10 mg/kg | — | 14/26 (53.8%) | 24/26 (92.3%) |
| Event | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/13 | 1/178 | 0/26 |
| Arthritis bacterialInfections and infestations | 1/13 | 0/178 | 0/26 |
| GastroenteritisInfections and infestations | 1/13 | 1/178 | 0/26 |
| Femur fractureInjury, poisoning and procedural complications | 1/13 | 1/178 | 0/26 |
| Rib fractureInjury, poisoning and procedural complications | 1/13 | 0/178 | 0/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/13 | 0/178 | 0/26 |
| Foot deformityMusculoskeletal and connective tissue disorders | 1/13 | 4/178 | 0/26 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/13 | 1/178 | 2/26 |
| DeafnessEar and labyrinth disorders | 0/13 | 0/178 | 1/26 |
| CataractEye disorders | 0/13 | 1/178 | 1/26 |
| Event | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/13 | 103/178 | 12/26 |
| Blood pressure increasedInvestigations | 2/13 | 27/178 | 12/26 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 5/13 | 28/178 | 2/26 |
| StomatitisGastrointestinal disorders | 4/13 | 46/178 | 3/26 |
| CystitisInfections and infestations | 4/13 | 11/178 | 0/26 |
| White blood cell count increasedInvestigations | 1/13 | 29/178 | 7/26 |
| White blood cells urine positiveInvestigations | 3/13 | 18/178 | 3/26 |
| Lymphocyte count decreasedInvestigations | 1/13 | 35/178 | 5/26 |
| ConstipationGastrointestinal disorders | 0/13 | 21/178 | 5/26 |
| Alanine aminotransferase increasedInvestigations | 2/13 | 29/178 | 2/26 |
| Age Continuous(years) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 52.8 ± 11.6 | 53.2 ± 11.5 | 57.8 ± 10.6 | 53.8 ± 11.4 |
| Age, Customized(participants) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| 20 - 29 years | 1 | 7 | 0 | 8 |
| 30 - 39 years | 2 | 13 | 1 | 16 |
| 40 - 49 years | 0 | 39 | 5 | 44 |
| 50 - 59 years | 6 | 70 | 7 | 83 |
| ≥ 60 years | 4 | 49 | 13 | 66 |
| Sex: Female, Male(Participants) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| Female | 12 | 146 | 19 | 177 |
| Male | 1 | 32 | 7 | 40 |
| Weight(kg) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 9.7 | 56.9 ± 9.4 | 53.9 ± 10.8 | 56.5 ± 9.6 |
| Duration of Rheumatoid Arthritis(participants) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| <= 2 years | 0 ± 9.0 | 24 ± 7.3 | 2 ± 10.1 | 26 ± 7.9 |
| >2 to <= 5 years | 2 | 45 | 4 | 51 |
| > 5 to <= 10 years | 2 | 57 | 12 | 71 |
| > 10 years | 9 | 52 | 8 | 69 |
| American College of Rheumatology (ACR) Functional Status Classification(participants) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| Class I | 0 | 29 | 0 | 29 |
| Class II | 12 | 112 | 17 | 141 |
| Class III | 1 | 37 | 9 | 47 |
| Class IV | 0 | 0 | 0 | 0 |
| Number of Tender Joints(joints) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 8.4 ± 5.2 | 14.3 ± 11.2 | 22.7 ± 13.3 | 14.9 ± 11.6 |
| Number of Swollen Joints(joints) | Participants From Phase I Study (IM101-034); Abatacept 10mg/kg | Participants From Phase II Study(IM101-071); Abatacept 10mg/kg | New Participants With MTX Intolerance; Abatacept 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 9.1 ± 4.7 | 11.6 ± 8.7 | 17.2 ± 10.0 | 12.1 ± 8.9 |
9 further baseline measures are reported on the registry.
The record gives a start of Dec 2006, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept